¹é½Å ±â¼ú ½ÃÀå : ±â¼úº°, ÀûÀÀ Áúȯº°, Åõ¿© °æ·Îº°, ¿¬·ÉÃþº°, À¯Åë ä³Îº°, Áö¿ªº°
Vaccine Technologies Market, By Technology, By Disease Indication, By Route of Administration, By Age Group, By Distribution Channel, By Geography
»óǰÄÚµå
:
1741369
¸®¼Ä¡»ç
:
Coherent Market Insights
¹ßÇàÀÏ
:
2025³â 03¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹®
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¹é½Å ±â¼ú ½ÃÀåÀº 2025³â¿¡´Â 554¾ï 4,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ°í, 2032³â¿¡´Â 1,115¾ï 2,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025³âºÎÅÍ 2032³â±îÁöÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)Àº 10.5%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.
º¸°í ¹üÀ§ |
º¸°í¼ ¼¼ºÎÁ¤º¸ |
±âÁØ ¿¬µµ |
2024³â |
½ÃÀå ±Ô¸ð(2025³â) |
554¾ï 4,000¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ |
2020-2024³â |
¿¹Ãø ±â°£ |
2025-2032³â |
¿¹Ãø±â°£(2025-2032³â) CAGR |
10.50% |
°¡Ä¡ ¿¹Ãø(2032³â) |
1,115¾ï 2,000¸¸ ´Þ·¯ |
¹é½Å ±â¼úÀº ¹é½ÅÀ» ¸¸µå´Â µ¥ »ç¿ëµÇ´Â ¹æ¹ý°ú Àü·«À» ¸»ÇÕ´Ï´Ù. ¹é½ÅÀº ƯÁ¤ Áúº´¿¡ ´ëÇÑ ¸é¿ª·ÂÀ» Çâ»ó½ÃŰ´Â »ý¹°ÇÐÀû ¹°ÁúÀÔ´Ï´Ù. ÀÌ Çõ½ÅÀûÀÎ ¹æ¹ýÀº mRNA, ¹ÙÀÌ·¯½º º¤ÅÍ, ´Ü¹éÁú ¼ºê À¯´Ö, DNA ±â¹Ý Ç÷§Æû µî ´Ù¾çÇÑ Á¢±Ù¹ýÀ» ÀÌ¿ëÇϰí ÀÖ½À´Ï´Ù. ÷´Ü±â¼úÀº ½Å¼ÓÇÑ °³¹ß°ú »õ·Î¿î º´¿øÃ¼¿¡ÀÇ ÀûÀÀÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¸é¿ª°è¸¦ ÀÚ±ØÇÏ¿© ƯÁ¤ Áúº´À» ÀνÄÇÏ°í ½Î¿ì°Ô ÇÔÀ¸·Î½á, ÀÌ·¯ÇÑ ¹é½ÅÀº ¼¼°èÀÇ °Ç°°úÁ¦¿¡ ÀÇÇØ È¿°úÀûÀ¸·Î ÀÓÇϱâ À§ÇÑ À¯¸ÁÇÑ ¼ö´ÜÀ» Á¦°øÇÕ´Ï´Ù. Àû±ØÀûÀ̰í Á¤È®ÇÑ Áúº´ °ü¸®ÀÇ »õ·Î¿î ½Ã´ë°¡ µµ·¡Çß½À´Ï´Ù.
½ÃÀå ¿ªÇÐ :
±ÔÁ¦ ´ç±¹¿¡ ÀÇÇÑ Á¦Ç° Çã°¡ Áõ°¡´Â ¿¹Ãø ±â°£¿¡ ÀÖ¾î¼ ¼¼°èÀÇ ¹é½Å ±â¼ú ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 12¿ù ´Ù±¹Àû Á¦¾àȸ»çÀÎ ´ÙÄÉ´ÙÁ¦¾àÀº À¯·´À§¿øÈ¸(EC)°¡ À¯·´¿¬ÇÕ(EU)¿¡¼ 4¼¼ ÀÌ»óÀÇ µ±â¿ ¿¹¹æÀ» À§ÇÑ ÀÚ»çÀÇ µ±â¿ ¹é½Å Å¥µ§°¡(µ±â¿ 4°¡ ¹é½Å[»ý¹é½Å, ¾àµ¶È])(TAK-003)¿¡ ´ëÇØ ÆÇ¸Å Çã°¡¸¦ ºÎ¿©Çß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ¶ÇÇÑ 2021³â 6¿ù¿¡´Â ¹ÙÀÌ¿À Á¦¾à ȸ»çÀΠĵ½Ã³ë¹ÙÀÌ¿À°¡ Áß±¹ ±¹°¡¾àǰ°¨µ¶°ü¸®±¹(NMPA)À¸·ÎºÎÅÍ ¸àÆä½Ã¾Æ¶ó´Â »óǰ¸íÀ» °¡Áø ±×·ì C ¹× ±×·ì A ¼ö¸·±¸±Õ Á¢ÇÕ ¹é½Å¿¡ ´ëÇÑ ½ÂÀÎÀ» ¹Þ¾Ò´Ù°í ¹ßÇ¥Çß½À´Ï´Ù.
º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡
- º» º¸°í¼¿¡¼´Â ¼¼°èÀÇ ¹é½Å ±â¼ú ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇßÀ¸¸ç, 2024³âÀ» ±âÁØ¿¬µµ·Î ÇÑ ¿¹Ãø ±â°£ 2025-2032³â ½ÃÀå ±Ô¸ð ¹× º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR%)À» Á¦°øÇÕ´Ï´Ù.
- ¶Ç, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ±âȸ¸¦ ¹àÇô, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¿¡ ´ëÇØ¼ ÇØ¼³Çß½À´Ï´Ù.
- ¶Ç ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç°ÀÇ »ó½Ã³ª ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤¿ëÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ Áß¿äÇÑ ÀλçÀÌÆ®µµ Á¦°øÇÕ´Ï´Ù.
- ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ½ÇÀû, Àü·« µîÀÇ ÆÄ¶ó¹ÌÅ͸¦ ¹ÙÅÁÀ¸·Î ¹é½Å ±â¼ú ½ÃÀå ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀ» Á¦°øÇÕ´Ï´Ù.
- º» º¸°í¼·ÎºÎÅÍÀÇ ÀλçÀÌÆ®¿¡ ÀÇÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ³ª ±â¾÷ÀÇ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° ¹ß¸Å, À¯Çü ¾÷±×·¹À̵å, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ °üÇÑ Á¤º¸¿¡ ±Ù°ÅÇÑ ÀÇ»ç °áÁ¤À» ½Ç½ÃÇÒ ¼ö ÀÖ½À´Ï´Ù.
- ¼¼°èÀÇ ¹é½Å ±â¼ú ½ÃÀå º¸°í¼´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ Áö¿øÇÕ´Ï´Ù.
- ÀÌÇØ°ü°èÀÚµéÀº ¹é½Å ±â¼ú ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç °áÁ¤ÀÌ ¿ëÀÌÇØÁý´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç
Á¦2Àå ½ÃÀå Àü¸Á
- º¸°í¼ ¼³¸í
- ÁÖ¿ä ¿ä¾à
- Coherent Opportunity Map(COM)
Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®
- ½ÃÀå ¿ªÇÐ
- ¼¼°èÀÇ °Ç° ¹®Á¦¿Í À¯Çà
- ±ÔÁ¦»óÀÇ °úÁ¦
- ÁÖ¿ä ½ÃÀå ±â¾÷ °£ ¶óÀ̼±½º °è¾à Áõ°¡
- ¿µÇ⠺м®
- ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
- ±ÔÁ¦ ½Ã³ª¸®¿À
- Á¦Ç° Ãâ½Ã/½ÂÀÎ
- PEST ºÐ¼®
- PORTER's ºÐ¼®
- ÇÕº´°ú Àμö ½Ã³ª¸®¿À
Á¦4Àå ¼¼°èÀÇ ¹é½Å ±â¼ú ½ÃÀå - Äڷγª ¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ
- COVID-19 ¿ªÇÐ
- °ø±ÞÃø°ú ¼ö¿äÃøÀÇ ºÐ¼®
- °æÁ¦¿¡ ¹ÌÄ¡´Â ¿µÇâ
Á¦5Àå ¼¼°èÀÇ ¹é½Å ±â¼ú ½ÃÀå, ±â¼úº°(2020-2032³â)
- »ý¾àµ¶È ¹é½Å
- ºÒÈ°È ¹é½Å
- ¼ºê À¯´Ö ¹é½Å
- Åå¼ÒÀÌµå ¹é½Å
- ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å
- ¸Þ½ÅÀú RNA(mRNA) ¹é½Å
Á¦6Àå ¼¼°èÀÇ ¹é½Å ±â¼ú ½ÃÀå, ÀûÀÀ Áúȯº°(2020-2032³â)
- °¨¿°Áõ Áúȯ
- ºñ°¨¿°¼º Áúȯ
Á¦7Àå ¼¼°èÀÇ ¹é½Å ±â¼ú ½ÃÀå, Åõ¿© °æ·Îº°(2020-2032³â)
Á¦8Àå ¼¼°èÀÇ ¹é½Å ±â¼ú ½ÃÀå, ¿¬·ÉÃþº°(2020-2032³â)
Á¦9Àå ¼¼°èÀÇ ¹é½Å ±â¼ú ½ÃÀå, À¯Åë ä³Îº°(2020-2032³â)
Á¦10Àå ¼¼°èÀÇ ¹é½Å ±â¼ú ½ÃÀå, Áö¿ªº°(2020-2032³â)
- ºÏ¹Ì
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÀÌÅ»¸®¾Æ
- ÇÁ¶û½º
- ½ºÆäÀÎ
- ·¯½Ã¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- Àεµ
- ÀϺ»
- ASEAN
- È£ÁÖ
- Çѱ¹
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- ºê¶óÁú
- ¸ß½ÃÄÚ
- ¾Æ¸£ÇîÆ¼³ª
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
- 秵- ¾ÆÇÁ¸®Ä«
- ºÏ¾ÆÇÁ¸®Ä«
- Áß¾Ó ¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«
Á¦11Àå °æÀï ±¸µµ
- Pfizer-BioNTech
- Moderna
- Johnson & Johnson
- AstraZeneca
- Sanofi
- Novavax
- GSK
- Sinovac Biotech
- Bharat Biotech
- Emergent BioSolutions
- Dynavax Technologies
- CureVac
- Valneva
- Takeda Pharmaceutical Company Limited
Á¦12Àå ¼½¼Ç
KTH
¿µ¹® ¸ñÂ÷
Vaccine Technologies Market is estimated to be valued at USD 55.44 Bn in 2025 and is expected to reach USD 111.52 Bn by 2032, growing at a compound annual growth rate (CAGR) of 10.5% from 2025 to 2032.
Report Coverage |
Report Details |
Base Year: |
2024 |
Market Size in 2025: |
USD 55.44 Bn |
Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: |
10.50% |
2032 Value Projection: |
USD 111.52 Bn |
Vaccine technology refers to the methods and strategies used to create vaccines. Vaccines are biological substances that can improve immunity to a particular disease. They prepare the body's immune system to fight off specific infections. Vaccine technologies have witnessed remarkable advancements, revolutionizing disease prevention. These innovative methods utilize various approaches such as mRNA, viral vector, protein subunit, and DNA-based platforms. Unlike traditional vaccines, these cutting-edge technologies enable rapid development and adaption to emerging pathogens. By stimulating the immune system to recognize and combat specific diseases, these vaccines offer promising avenues to tackle global health challenges more effectively. As a result, the landscape of immunization has evolved, ushering in a new era of proactive and precise disease control. Vaccine technologies includes live-attenuated vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, viral vector vaccines, messenger rna (mrna) vaccines.
Market Dynamics:
Increasing product approval by the regulatory authorities is expected to drive the growth of the global vaccine technologies market over the forecast period. For instance, in December 2022, Takeda Pharmaceutical Company Limited, a multinational pharmaceutical company, announced that the European Commission (EC) had granted marketing authorization for the company's dengue vaccine QDENGA (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) for the prevention of dengue disease in individuals from four years of age in the European Union (EU). Moreover, in June 2021, CanSinoBIO, a biopharmaceutical company, announced that the National Medical Products Administration (NMPA) of China granted approval for its Group C and Group A Meningococcal Conjugate Vaccine which has the trade name Menphecia. Menphecia delivers protection against infection with Group A and C Neisseria meningitides.
Key features of the study:
- This report provides an in-depth analysis of the global vaccine technologies market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the vaccine technologies market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer-BioNTech, Moderna, Johnson & Johnson, AstraZeneca, Sanofi, Novavax, GSK, Sinovac Biotech, Bharat Biotech, Emergent BioSolutions, Dynavax Technologies, CureVac, Valneva, and Takeda Pharmaceutical Company Limited.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global vaccine technologies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the vaccine technologies market
Detailed Segmentation:
- Global Vaccine Technologies Market, By Technology:
- Live-attenuated vaccines
- Inactivated vaccines
- Subunit vaccines
- Toxoid vaccines
- Viral vector vaccines
- Messenger RNA (mRNA) vaccines
- Global Vaccine Technologies Market, By Disease Indication:
- Infectious Diseases
- Non-Infectious Diseases
- Global Vaccine Technologies Market, By Route of Administration:
- Global Vaccine Technologies Market, By Age Group:
- Global Vaccine Technologies Market, By Distribution Channel:
- Public Sector
- Private Sector
- Global Vaccine Technologies Market, By Geography:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profile:
- Pfizer-BioNTech
- Moderna
- Johnson & Johnson
- AstraZeneca
- Sanofi
- Novavax
- GSK
- Sinovac Biotech
- Bharat Biotech
- Emergent BioSolutions
- Dynavax Technologies
- CureVac
- Valneva
- Takeda Pharmaceutical Company Limited
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Vaccine Technologies, By Technology
- Market Vaccine Technologies, By Disease Indication
- Market Vaccine Technologies, By Route of Administration
- Market Vaccine Technologies, By Age Group
- Market Vaccine Technologies, By Distribution Channel
- Market Vaccine Technologies, By Geography
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Global Health Concerns and Pandemics
- Regulatory Challenges
- Increasing License Agreement among Key Market Players
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Vaccine Technologies Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Vaccine Technologies Market, By Technology, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Live-attenuated vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Inactivated vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Subunit vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Toxoid vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Viral vector vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Messenger RNA (mRNA) vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
6. Global Vaccine Technologies Market, By Disease Indication, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Non-Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
7. Global Vaccine Technologies Market, By Route of Administration, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Nasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
8. Global Vaccine Technologies Market, By Age Group, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
9. Global Vaccine Technologies Market, By Distribution Channel, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Public Sector
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Private Sector
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
10. Global Vaccine Technologies Market, By Region, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, By Country, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Country 2021 -2032
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution , 2020-2032, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn)
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn)
- North Africa
- Central Africa
- South Africa
11. Competitive Landscape
- Pfizer-BioNTech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Moderna
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novavax
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GSK
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sinovac Biotech
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bharat Biotech
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Emergent BioSolutions
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Dynavax Technologies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- CureVac
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Valneva
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
12. Section
- Research Methodology
- About us
°ü·ÃÀÚ·á